Sansure Biotech (688289) Stock Overview

Sansure Biotech Inc. engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments in China. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; and diagnostic kits for monkeypox, epstein-barr virus, and human cytomegalovirus DNA, as well as rapid antigen tests. The company also provides nucleic acid extraction or purification kits, multi-type sample DNA/RNA extraction-purification kits, and sample release reagents; sample storage reagents for SARS-CoV-2; extraction instruments and systems; and PCR instruments comprising real-time quantitative thermal cyclers, portable molecule workstations, and real-time PCR systems. In addition, it engages in the research and development, production, and sale of drugs; procurement and sale of raw materials; manufacture of instruments; manufacture and sale of electronic equipment; trading; investment advisory; medical research and experimental development; and internet sales, as well as offers third-party medical testing and biotechnology development services. The company was founded in 2008 and is headquartered in Changsha, China.